The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I safety and tolerability of once daily oral afatinib (A) in combination with docetaxel (D) in patients (pts) with relapsed or refractory advanced solid tumors.
Helene Senellart
No relevant relationships to disclose
Jaafar Bennouna
Consultant or Advisory Role - Amgen
Honoraria - Boehringer Ingelheim; Roche
Nicolas Isambert
No relevant relationships to disclose
Helene De-Montserrat
No relevant relationships to disclose
Patrick J. Squiban
Employment or Leadership Position - Boehringer Ingelheim
Inga Tschoepe
Employment or Leadership Position - Boehringer Ingelheim
Jean-Pierre Delord
No relevant relationships to disclose